Abatacept

Generic Name
Abatacept
Brand Names
Orencia
Drug Type
Biotech
Chemical Formula
-
CAS Number
332348-12-6
Unique Ingredient Identifier
7D0YB67S97
Background

Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of tw...

Indication

Abatacept is indicated in adult patients for the treatment of moderately-to-severely active rheumatoid arthritis and for the treatment of active psoriatic arthritis. In patients two years of age and older, abatacept is also indicated for the treatment of moderately-to-severely active juvenile idiopathic arthritis.
...

Associated Conditions
Acute Graft-Versus-Host Disease (GVHD), Moderate to Severe Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Polyarticular juvenile rheumatoid arthritis, chronic or unspecified, Psoriatic Arthritis
Associated Therapies
-
Clinical Trials
Related News

A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis

First Posted Date
2014-06-11
Last Posted Date
2020-02-17
Lead Sponsor
Dinesh Khanna, MD, MS
Target Recruit Count
88
Registration Number
NCT02161406
Locations
🇺🇸

NorthWell Health, Great Neck, New York, United States

🇨🇦

Mount Sinai Hospital, Toronto, Ontario, Canada

🇺🇸

Arthritis Associates of Southern California, Los Angeles, California, United States

and more 24 locations

Long Term Experience With Abatacept in Routine Clinical Practice

Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: Abatacept
First Posted Date
2014-04-10
Last Posted Date
2017-04-19
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
2364
Registration Number
NCT02109666
Locations
🇨🇭

Local Institution, Basel, Switzerland

Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)

First Posted Date
2014-04-09
Last Posted Date
2024-07-29
Lead Sponsor
University of South Florida
Target Recruit Count
65
Registration Number
NCT02108860
Locations
🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

🇨🇦

University of Calgary, Calgary, Alberta, Canada

🇺🇸

Vanderbilt University, Nashville, Tennessee, United States

and more 17 locations

Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background

Not Applicable
Withdrawn
Conditions
Rheumatoid Arthritis
Chronic Hepatitis B
Interventions
Drug: Placebo
Drug: Abatacept
First Posted Date
2014-02-04
Last Posted Date
2020-11-16
Lead Sponsor
University of California, Los Angeles
Registration Number
NCT02053727
Locations
🇺🇸

Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, California, United States

Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting

Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: Abatacept
First Posted Date
2014-01-16
Last Posted Date
2018-02-07
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
153
Registration Number
NCT02037737

Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study

First Posted Date
2014-01-06
Last Posted Date
2017-01-09
Lead Sponsor
The Cleveland Clinic
Registration Number
NCT02027298
Locations
🇺🇸

Cleveland Clinic, Cleveland, Ohio, United States

An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata

Phase 2
Completed
Conditions
Alopecia Areata
Interventions
Drug: Abatacept
First Posted Date
2013-12-23
Last Posted Date
2019-04-30
Lead Sponsor
Columbia University
Target Recruit Count
15
Registration Number
NCT02018042
Locations
🇺🇸

Columbia University Medical Center - Department of Dermatology, New York, New York, United States

Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)

Phase 1
Completed
Conditions
Chronic Graft Versus Host Disease
Interventions
Drug: Abatacept
First Posted Date
2013-10-07
Last Posted Date
2024-01-18
Lead Sponsor
Beth Israel Deaconess Medical Center
Target Recruit Count
56
Registration Number
NCT01954979
Locations
🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Bone Marrow Transplant With Abatacept for Non-Malignant Diseases

First Posted Date
2013-08-07
Last Posted Date
2019-12-26
Lead Sponsor
Emory University
Target Recruit Count
10
Registration Number
NCT01917708
Locations
🇺🇸

Children's Healthcare of Atlanta, Atlanta, Georgia, United States

A Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata

Phase 2
Withdrawn
Conditions
Alopecia Areata
Interventions
Drug: placebo
Drug: Abatacept
First Posted Date
2013-08-06
Last Posted Date
2014-07-24
Lead Sponsor
Columbia University
Registration Number
NCT01917058
Locations
🇺🇸

Columbia University Medical Center, Dept of Dermatology, New York, New York, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy